Risk Factors of Porphyria Cutanea Tarda (PCT)

Porphyria Cutanea Tarda Clinical Trial

Official title:
“Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus”

Status Completed

Clinical Trial Summary

Comparison of patients with documented PCT and HCV infection, documented PCT without HCV, HCV infection without PCT and controls without HCV or PCT.

Single blood + urine sample uptake to investigate : mutations in HFE gene, uroporphyrinogen decarboxylase activity, HCV genotye, history of disease.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Longitudinal

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00213772
Study type	Observational
Source	University Hospital, Strasbourg, France
Contact
Status	Completed
Phase	N/A
Start date	May 1999

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03118674` - Harvoni Treatment Porphyria Cutanea Tarda	Phase 2
Completed	`NCT00005103` - Study of the Pathogenesis of Porphyria Cutanea Tarda	N/A
Completed	`NCT01573754` - Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda	Phase 2
Recruiting	`NCT01284946` - Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda	Phase 2
Completed	`NCT00599326` - Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda	Phase 3